CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma
Givechian KB, Garner C, Garban H, Rabizadeh S, Soon-Shiong P. CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. Oncotarget 2018, 9: 29743-29752. PMID: 30038717, PMCID: PMC6049856, DOI: 10.18632/oncotarget.25701.Peer-Reviewed Original ResearchBladder urothelial carcinomaPoor overall survivalUrothelial carcinomaOverall survivalBladder urothelial carcinoma patientsUrothelial carcinoma patientsPlatinum-based therapyMechanisms of chemoresistancePatient tumor samplesRepair genesSystemic chemotherapyFavorable survivalNucleotide excision repair genesWorse survivalCarcinoma patientsPoor survivalTherapeutic strategiesTherapy resistancePyrimidine synthesis pathwayRepair processClinical targetsTumor samplesPatientsCarcinomaDNA repair genesIdentification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples
Givechian KB, Wnuk K, Garner C, Benz S, Garban H, Rabizadeh S, Niazi K, Soon-Shiong P. Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. Npj Genomic Medicine 2018, 3: 14. PMID: 29928512, PMCID: PMC5998068, DOI: 10.1038/s41525-018-0054-7.Peer-Reviewed Original ResearchFavorable clinical featuresTumor microenvironmentTumor samplesGene signatureClinical featuresT cellsImmune gene expression signatureAntitumor activityT cell abundanceCohort of patientsFavorable clinical outcomeRegulatory T cellsAdaptive immune responsesImmunogenic tumor microenvironmentClusters of patientsPatient tumor samplesM1 macrophage subtypeTreg enrichmentTreg studiesImmunogenic tumorsGene expression signaturesOverall survivalClinical outcomesClinical associationsPatient prognosis